Kiniksa Pharmaceuticals International (KNSA) Stock Price, News & Analysis

Company Overview

Kiniksa Pharmaceuticals International, Inc. is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome. Beyond Ilaris, Kiniksa’s clinical pipeline includes mavrilimumab, a monoclonal antibody targeting the GM-CSF receptor being investigated for giant cell arteritis; remibrutinib, a selective BTK inhibitor in Phase III studies for chronic spontaneous urticaria; and pozelimab, an anti-C5 monoclonal antibody under development for rare complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria and myasthenia gravis.

Kiniksa operates globally, with commercial and development activities spanning North America, Europe and Asia under various licensing and distribution arrangements. The company is led by Founder and Chief Executive Officer John H. Johnson, who oversees a management team composed of experienced biopharmaceutical executives and scientific leaders. By combining strategic partnerships, disciplined capital allocation and a targeted R&D strategy, Kiniksa aims to deliver therapies that can transform the treatment landscape for patients with serious immune diseases.

Key Stats

• Today's Range: $35.41 to $35.98
• 50-Day Range: $26.33 to $37.10
• 52-Week Range: $17.82 to $37.34
• Volume: 123,125 shs
• Average Volume: 659,595 shs
• Market Capitalization: $2.65 billion
• P/E Ratio: 892.72
• Dividend Yield: N/A
• Price Target: $41.17
• Consensus Rating: Buy

Kiniksa Pharmaceuticals International Stock Analysis - MarketRank™

Kiniksa Pharmaceuticals International scored higher than 57% of companies evaluated by MarketBeat, and ranked 565th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Buy

Consensus Rating

Kiniksa Pharmaceuticals International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Kiniksa Pharmaceuticals International has a consensus price target of $41.17, representing about 15.6% upside from its current price of $35.61.

Amount of Analyst Coverage

Kiniksa Pharmaceuticals International has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kiniksa Pharmaceuticals International are expected to grow in the coming year, from ($0.55) to $0.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kiniksa Pharmaceuticals International is 890.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 280.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kiniksa Pharmaceuticals International is 890.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 77.01.

Price to Book Value per Share Ratio

Kiniksa Pharmaceuticals International has a P/B Ratio of 5.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.86% of the float of Kiniksa Pharmaceuticals International has been sold short.

Short Interest Ratio / Days to Cover

Kiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiniksa Pharmaceuticals International has recently increased by 29.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kiniksa Pharmaceuticals International does not currently pay a dividend.

Dividend Growth

Kiniksa Pharmaceuticals International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.86% of the float of Kiniksa Pharmaceuticals International has been sold short.

Short Interest Ratio / Days to Cover

Kiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiniksa Pharmaceuticals International has recently increased by 29.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.30

News Sentiment

Kiniksa Pharmaceuticals International has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Kiniksa Pharmaceuticals International this week, compared to 6 articles on an average week.

Search Interest

10 people have searched for KNSA on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kiniksa Pharmaceuticals International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,227,065.00 in company stock.

Percentage Held by Insiders

53.48% of the stock of Kiniksa Pharmaceuticals International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.95% of the stock of Kiniksa Pharmaceuticals International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KNSA Stock Analysis - Frequently Asked Questions

How have KNSA shares performed this year?

Kiniksa Pharmaceuticals International's stock was trading at $19.78 at the beginning of the year. Since then, KNSA shares have increased by 80.0% and is now trading at $35.6050.

How were Kiniksa Pharmaceuticals International's earnings last quarter?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday, July, 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a trailing twelve-month return on equity of 1.05% and a net margin of 0.90%.
Read the conference call transcript.

When did Kiniksa Pharmaceuticals International IPO?

Kiniksa Pharmaceuticals International (KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals International's major shareholders?

Top institutional investors of Kiniksa Pharmaceuticals International include Rubric Capital Management LP (5.28%), Acadian Asset Management LLC (1.74%), Braidwell LP (1.49%) and Qube Research & Technologies Ltd (1.20%). Insiders that own company stock include Sanj K Patel, John F Paolini, Eben Tessari, Michael R Megna, Mark Ragosa, Barry D Quart and Ross Moat.
View institutional ownership trends.

How do I buy shares of Kiniksa Pharmaceuticals International?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kiniksa Pharmaceuticals International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals International investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KNSA
• CIK: 1730430
• Web: www.kiniksa.com
• Phone: (781) 431-9100
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kiniksa Pharmaceuticals International: $41.17
• High Price Target: $54.00
• Low Price Target: $35.00
• Potential Upside/Downside: +15.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.04
• Trailing P/E Ratio: 893.10
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.19 million
• Net Margins: 0.90%
• Pretax Margin: 2.69%
• Return on Equity: 1.05%
• Return on Assets: 0.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.57
• Quick Ratio: 3.16

Sales & Book Value

• Annual Sales: $423.24 million
• Price / Sales: 6.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.60 per share
• Price / Book: 5.40

Miscellaneous

• Outstanding Shares: 74,110,000
• Free Float: 34,475,000
• Market Cap: $2.64 billion
• Optionable: Optionable
• Beta: 0.20